Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882172 | 1.00 | PIM1 (0.55) | PIM1PIM2PTPN1CISD1TTR | |
| SCHEMBL2881861 | 0.90 | PIM1 (0.57) | PIM1PIM2PTPN1CISD1TTR | |
| SCHEMBL2881863 | 0.90 | PIM1 (0.57) | PIM1PIM2PTPN1CISD1TTR | |
| SCHEMBL6422799 | 0.87 | HPGD (0.52) | PIM1PIM2PTPN1CISD1PIK3CG | |
| SCHEMBL2877670 | 0.87 | HPGD (0.52) | PIM1PIM2PTPN1CISD1PIK3CG | |
| SCHEMBL2877667 | 0.87 | HPGD (0.52) | PIM1PIM2PTPN1CISD1PIK3CG | |
| SCHEMBL2882113 | 0.83 | HPGD (0.56) | PTPN1CISD1PIK3CGMGAMGAA | |
| SCHEMBL2882116 | 0.83 | HPGD (0.56) | PTPN1CISD1PIK3CGMGAMGAA | |
| SCHEMBL2883617 | 0.82 | PDE4B (0.58) | PIM1PIM2MGAMGAASI | |
| SCHEMBL2883618 | 0.82 | PDE4B (0.58) | PIM1PIM2MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | PIM1 2247/4885PIM2 2814/4885PTPN1 277/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | PIM1 201/4885PIM2 264/4885PTPN1 436/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | PIM1 2811/4885PIM2 2494/4885PTPN1 4272/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | PIM1 864/4885PIM2 1010/4885PTPN1 639/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | PIM1 2412/4885PIM2 2938/4885PTPN1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.